Related Experiment Videos
Neuropeptide Y counteracts interferon-alpha-induced anorexia
N P Turrin1, M C Flynn, C R Plata-Salamán
1Division of Molecular Biology, School of Life and Health Sciences, University of Delaware, Newark, DE, USA.
Neuroimmunomodulation
|September 4, 1999
Summary
Neuropeptide Y (NPY) can counteract anorexia caused by Interferon-alpha (IFN-alpha) immunotherapy in rats. This finding suggests NPY may help manage a key side effect of IFN-alpha treatments.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Interferon-alpha (IFN-alpha) immunotherapy can cause neurological side effects, notably anorexia, limiting treatment efficacy.
- Developing strategies to mitigate these neurological effects without compromising immunotherapy is crucial.
Purpose of the Study:
- To investigate if neuropeptide Y (NPY), a feeding-enhancing peptide, can inhibit IFN-alpha-induced anorexia in a rat model.
- To assess the potential of NPY as an intervention for IFN-alpha associated anorexia.
Main Methods:
- Rats received central administration of Interferon-alpha (IFN-alpha) into the third cerebral ventricle.
- Neuropeptide Y (NPY) was administered concomitantly or at different time points relative to IFN-alpha.
- Anorexia was quantified as a measure of IFN-alpha's neurological effect.
Main Results:
- IFN-alpha induced significant anorexia at an immunotherapeutically relevant dose.
- Heat-inactivated IFN-alpha did not produce anorexia.
- NPY administration counteracted IFN-alpha-induced anorexia when given before, after, or concurrently with IFN-alpha.
Conclusions:
- Neuropeptide Y effectively inhibits anorexia induced by Interferon-alpha in rats.
- NPY and its agonists show promise as a novel therapeutic strategy to manage anorexia during IFN-alpha immunotherapy.